Summary - Funding Rounds

Founding Date

2008

Total Funding

$248.7 m

Investors

Karyopharm Therapeutics is a subsidiary of Biogen

Karyopharm Therapeutics Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

387.0k229.0k250.0k

Revenue growth, %

(41%)9%

R&D expense

28.5m60.1m97.7m86.9m

General and administrative expense

5.9m15.9m21.6m23.9m

Operating expense total

34.3m76.1m119.3m110.9m

EBIT

(33.9m)(75.8m)(119.1m)(110.7m)

EBIT margin, %

(8773%)(33121%)(47630%)

Interest expense

1.0k1.0k

Interest income

3.0k97.0k897.0k1.3m

Pre tax profit

(109.4m)

Income tax expense

(139.0k)

Net Income

(33.9m)(75.8m)(118.2m)(109.6m)

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

R&D expense

11.0m13.2m16.0m20.8m27.0m25.9m21.8m24.6m19.9m24.1m23.1m25.2m41.3m86.1m

General and administrative expense

2.9m3.3m3.8m5.4m6.2m4.8m5.6m6.0m5.9m6.3m6.6m5.8m7.6m17.1m

Operating expense total

13.9m16.5m19.8m26.2m33.2m30.7m27.3m30.5m25.8m30.3m29.8m31.1m48.9m103.2m

EBIT

(13.7m)(16.4m)(19.7m)(26.1m)(33.0m)(30.6m)(27.3m)(30.5m)(25.7m)(30.3m)(29.8m)(31.1m)(38.9m)(73.3m)

Interest expense

18.0k

Interest income

18.0k17.0k20.0k141.0k267.0k239.0k286.0k329.0k311.0k400.0k412.0k454.0k509.0k1.2m

Pre tax profit

(29.9m)(29.4m)(30.6m)(38.4m)(72.1m)

Income tax expense

(23.0k)(18.0k)(13.0k)(12.0k)5.0k

Net Income

(13.7m)(16.4m)(19.7m)(26.1m)(32.7m)(30.4m)(27.1m)(30.2m)(25.4m)(29.9m)(29.4m)(30.6m)(38.5m)(72.1m)

Karyopharm Therapeutics Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

156.0m150.6m58.4m49.7m

Inventories

2.0m2.0m2.0m2.1m

Current Assets

158.0m207.8m177.6m131.6m

PP&E

240.0k2.8m3.5m2.8m

Total Assets

158.2m220.3m215.4m180.4m

Accounts Payable

1.7m6.3m3.8m4.8m

Current Liabilities

3.3m12.3m15.1m16.5m

Total Liabilities

18.1m

Additional Paid-in Capital

217.5m345.2m455.2m528.6m

Retained Earnings

(138.3m)(256.5m)(366.1m)

Total Equity

154.9m206.8m198.4m162.2m

Financial Leverage

1 x1.1 x1.1 x1.1 x

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

144.9m132.3m227.1m51.5m24.2m43.5m42.2m37.7m43.9m25.6m55.4m54.5m37.5m119.0m

Current Assets

147.6m135.3m231.3m249.3m225.3m198.3m138.1m124.2m130.3m112.2m145.7m121.7m133.3m244.6m

PP&E

322.0k604.0k2.7m3.3m3.2m3.7m3.3m3.2m3.0m2.7m2.5m2.3m2.5m2.6m

Total Assets

149.3m137.7m235.2m292.0m263.3m237.0m192.1m170.9m183.6m155.4m185.8m163.8m146.4m256.6m

Accounts Payable

3.3m3.5m2.1m7.0m4.5m4.6m4.1m4.1m2.2m4.2m3.2m1.9m4.9m3.8m

Current Liabilities

5.0m5.6m6.2m14.7m14.1m14.4m13.2m15.5m15.0m15.5m17.5m21.2m46.7m36.5m

Total Liabilities

6.0m7.4m16.5m16.0m16.4m15.1m17.3m16.7m17.1m19.0m22.6m50.8m43.1m

Additional Paid-in Capital

220.4m224.4m340.2m439.9m444.6m448.1m460.5m467.2m506.1m534.8m592.5m597.6m629.6m781.2m

Retained Earnings

(92.7m)(112.4m)(164.4m)(197.1m)(227.5m)(283.6m)(313.7m)(339.2m)(396.3m)(425.7m)(456.3m)(533.8m)(567.5m)

Total Equity

144.1m131.7m227.8m275.5m247.3m220.6m177.0m153.6m166.9m138.4m166.7m141.2m95.5m213.5m

Financial Leverage

1 x1 x1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.2 x1.5 x1.2 x

Karyopharm Therapeutics Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(33.9m)(75.8m)(118.2m)(109.6m)

Depreciation and Amortization

144.0k323.0k634.0k717.0k

Inventories

(1.4m)(45.0k)(55.0k)(120.0k)

Accounts Payable

664.0k4.5m(2.4m)945.0k

Cash From Operating Activities

(30.3m)(51.4m)(94.0m)(84.4m)

Purchases of PP&E

(57.0k)(2.8m)(1.4m)(70.0k)

Cash From Investing Activities

(57.0k)(67.0m)(90.8m)24.6m

Cash From Financing Activities

185.9m113.1m92.7m51.2m

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018

Net Income

(13.7m)(16.4m)(19.7m)(26.1m)(32.7m)(30.4m)(27.1m)(30.2m)(25.4m)(29.9m)(38.5m)(72.1m)

Depreciation and Amortization

169.0k353.0k

Accounts Payable

3.5m2.1m7.0m4.5m4.6m4.1m4.1m2.2m4.2m(773.0k)(1.9m)

Cash From Operating Activities

(34.7m)(72.3m)

Purchases of PP&E

(382.0k)(779.0k)

Cash From Investing Activities

2.5m(25.1m)

Cash From Financing Activities

429.0k147.6m
Report incorrect company information

Karyopharm Therapeutics Operating Metrics

FY, 2015

Patents Issued

10
Report incorrect company information